139 related articles for article (PubMed ID: 26545782)
1. Administration of sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated GP100(25-33) peptide-coupled spleen cells effectively mounts antigen-specific immune response against mouse melanoma.
Chang X; Xia CQ
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):46-52. PubMed ID: 26545782
[TBL] [Abstract][Full Text] [Related]
2. Potent antigen-specific immune response induced by infusion of spleen cells coupled with succinimidyl-4-(N-maleimidomethyl cyclohexane)-1-carboxylate (SMCC) conjugated antigens.
Guo Y; Werbel T; Wan S; Wu H; Li Y; Clare-Salzler M; Xia CQ
Int Immunopharmacol; 2016 Feb; 31():158-68. PubMed ID: 26735611
[TBL] [Abstract][Full Text] [Related]
3. Infusion of Sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate-Conjugated MOG35-55-Coupled Spleen Cells Effectively Prevents and Reverses Experimental Autoimmune Encephalomyelitis in Mice.
Zhang L; Guo Y; Xia CQ
J Immunol Res; 2015; 2015():129682. PubMed ID: 26258148
[TBL] [Abstract][Full Text] [Related]
4. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
5. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
6. An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in
Zhang L; Song S; Jin X; Wan X; Shahzad KA; Pei W; Zhao C; Shen C
Cancer Immunol Res; 2019 Jul; 7(7):1188-1201. PubMed ID: 31113806
[TBL] [Abstract][Full Text] [Related]
7. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
[TBL] [Abstract][Full Text] [Related]
8. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
[TBL] [Abstract][Full Text] [Related]
9. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
10. Efficient amplification of melanoma-specific CD8+ T cells using artificial antigen presenting complex.
Chang J
Exp Mol Med; 2006 Dec; 38(6):591-8. PubMed ID: 17202834
[TBL] [Abstract][Full Text] [Related]
11. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.
Wang XY; Chen X; Manjili MH; Repasky E; Henderson R; Subjeck JR
Cancer Res; 2003 May; 63(10):2553-60. PubMed ID: 12750279
[TBL] [Abstract][Full Text] [Related]
12. Marked anti-tumor effects of CD8(+)CD62L(+) T cells from melanoma-bearing mice.
Liao Y; Geng P; Tian Y; Miao H; Liang H; Zeng R; Ni B; Ruan Z
Immunol Invest; 2015; 44(2):147-63. PubMed ID: 25122543
[TBL] [Abstract][Full Text] [Related]
13. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ
J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294
[TBL] [Abstract][Full Text] [Related]
14. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.
Fonsatti E; Nicolay HJ; Sigalotti L; Calabrò L; Pezzani L; Colizzi F; Altomonte M; Guidoboni M; Marincola FM; Maio M
Clin Cancer Res; 2007 Jun; 13(11):3333-8. PubMed ID: 17545540
[TBL] [Abstract][Full Text] [Related]
15. Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.
Molino NM; Neek M; Tucker JA; Nelson EL; Wang SW
Biomaterials; 2016 Apr; 86():83-91. PubMed ID: 26894870
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma.
Clemons-Miller AR; Chatta GS; Hutchins L; Angtuaco EJ; Ravaggi A; Santin AD; Cannon MJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):917s-924s. PubMed ID: 11300492
[TBL] [Abstract][Full Text] [Related]
17. Functionalisation of Virus-Like Particles Enhances Antitumour Immune Responses.
Kramer K; Al-Barwani F; Baird MA; Young VL; Larsen DS; Ward VK; Young SL
J Immunol Res; 2019; 2019():5364632. PubMed ID: 30729137
[TBL] [Abstract][Full Text] [Related]
18. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
[TBL] [Abstract][Full Text] [Related]
19. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]